Aaron Nelson
Principal & Managing Director @ Novartis Venture Fund
Boston, United States
Aaron Nelson is a Series A investor at Novartis Venture Fund in Boston focused on Biotechnology. Aaron Nelson - Principal & Managing Director @ Novartis Venture Fund
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Aaron Nelson invests in
Stages Aaron Nelson invests in
Countries Aaron Nelson invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells. | $85M / Series A / Jun 25, 2024 |
Co-Investors
About Novartis Venture Fund
Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, managementand board experience, and capital efficiency in the program.Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.
Novartis Venture Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Aaron Nelson
Principal & Managing Director
|
|||
Anja König
Global Head Novartis Venture Fund
|
|||
Bart Dzikowski
Managing Director, Head of Transactions & Legal
|
|||
Florent Gros
Managing Director
|
|||
Florent Gros
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Aaron Nelson invest in?
Aaron Nelson invests primarily in Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Aaron Nelson?
Public channels for Aaron Nelson include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Aaron Nelson last invest?
The most recent investment recorded for Aaron Nelson closed in Jun 2024. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
